<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01182415</url>
  </required_header>
  <id_info>
    <org_study_id>09-444</org_study_id>
    <nct_id>NCT01182415</nct_id>
  </id_info>
  <brief_title>High Dose Chemotherapy and Stem Cell Transplant for Non-Hodgkin's Lymphoma or Central Nervous System (CNS) Lymphoma</brief_title>
  <official_title>Phase II Trial of Hihg-Dose Thiotepa, Busulfan, Cyclophosphamide, and Rituximab With Autologous Stem Cell Transplantation for Patients With CNS Involvement by Non-Hodgkin's Lymphoma or Primary CNS Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Otsuka America Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Current standard treatments for lymphoma involving the central nervous system include
      chemotherapy or whole brain radiation therapy (WBRT). However, many patients do not respond
      to this treatment, and some of the patients who do respond relapse after treatment.

      Previous research has shown that a stem cell transplant of a patient's own cells (autologous
      stem cell transplant) may be more effective for some patients with lymphoma involving the
      CNS. In previous research using autologous stem cell transplants for lymphoma involving the
      CNS, a conditioning regimen consisting of the drugs thiotepa, busulfan and cyclophosphamide
      (TCE) was used. These drugs have been shown to enter the nervous system.

      In this research study, the investigators are adding the drug rituximab (Rituxan) to the drug
      cytarabine for the stem cell mobilization process. Cytarabine is a standard drug for
      mobilization. In addition, rituximab will be added to the conditioning regimen of thiotepa,
      busulfan and cyclophosphamide. Rituximab is approved by the FDA for the treatment of some
      types of lymphomas, but is not approved for use in lymphomas that involve the CNS. Rituximab
      is known to be able to enter the CNS. Previous research has suggested that it may help treat
      lymphoma that involves the CNS.

      The goal of this research study is to see if adding rituximab to the stem cell mobilization
      and conditioning regimens helps treat lymphoma that involves the central nervous system.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      If the screening procedures confirm that you are eligible to participate in the research
      study you will have the following procedures.

      Stem cell mobilization - this will take place over at least 9 days to prepare you to donate
      your stem cells for your autologous transplant. The drugs cytarabine, rituximab and Neupogen
      (G-CSF) will be given. You will be in the hospital for 2 days to receive the cytarabine
      infusions (and the 1st rituximab infusion of day 1 of stem cell mobilization). Then you will
      be discharged. You will receive the Neupogen injections as an outpatient.

      Stem cell collection (leukapheresis) - When your doctor determines that your stem cell count
      is high enough you will have your stem cells collected by a procedure called leukapheresis.
      Leukapheresis is performed by collecting blood from a vein and processing it through a
      machine that removes the stem cells that are needed to produce bone marrow. The rest of the
      blood is returned to you through another vein. The harvested stem cells will be frozen and
      stored. These cells will be returned to you after you complete the conditioning regimen with
      high dose chemotherapy.

      Conditioning regimen (high dose chemotherapy) - You will enter the hospital for the
      conditioning regimen and stay for about 30 days after you receive your stem cell transplant.
      The conditioning regimen to help kill cancer cells before your stem cell transplant will take
      place over 9 days. All drugs will be given intravenous (through an IV).

      Infusion of stem cells (stem cell transplant) - Your cells will be given to you through your
      vein, similar to an IV infusion. The infusion usually takes several hours.

      After you are discharged, you will be asked to return at about 4 weeks, 8 weeks, 12 weeks and
      14 weeks after the stem cell transplant. At each visit you will have a physical exam,
      questions to measure your mental functioning, blood tests. About 14 weeks after the stem cell
      transplant you will have an eye exam, echocardiogram, lung function tests, whole body PET-CT
      scan, brain MRI or CT scan, MRI or CT of spinal cord (for patients who may have lymphoma in
      the spinal cord), collection of cerebral spinal fluid, and bone marrow aspiration.

      You will have follow-up visits for 6 month to up to 4 years after the stem cell transplant.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Patients With CNS Involvement by B-cell NHL, Relapsed PCNSL, or Relapsed PIOL Who Are Alive and Progression-free at One Year</measure>
    <time_frame>3 years</time_frame>
    <description>The proportion of patients with central nervous system (CNS) involvement by B-cell Non-Hodgkin's Lymphoma (NHL), relapsed primary central nervous system lymphoma (PCNSL), or relapsed primary intraocular lymphoma (PIOL) who are alive and progression-free at one year</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>2-year Progression Free Survival (PFS)</measure>
    <time_frame>2 years</time_frame>
    <description>The percentage of participants alive and without disease progression at 2 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2-year Overall Survival (OS)</measure>
    <time_frame>2 years</time_frame>
    <description>The percentage of participants alive after two years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Rate</measure>
    <time_frame>3 years</time_frame>
    <description>The number of participants that achieved complete remission following high dose chemotherapy and autologous stem cell transplantation (ASCT). Complete remission is defined as the disappearance of all evidence of disease.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Non-Hodgkin's Lymphoma</condition>
  <condition>CNS Lymphoma</condition>
  <arm_group>
    <arm_group_label>High-dose chemotherapy with autologous stem cell transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autologous stem cell transplant</intervention_name>
    <description>Autologous stem cell transplant following high-dose chemotherapy</description>
    <arm_group_label>High-dose chemotherapy with autologous stem cell transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High-dose chemotherapy</intervention_name>
    <description>High-dose chemotherapy with rituximab, thiotepa, busulfan, and cyclosphosphamide</description>
    <arm_group_label>High-dose chemotherapy with autologous stem cell transplant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  One of the following clinical criteria:secondary CNS NHL; synchronous CNS NHL;
             relapsed PCNSL; relapsed IOL; PCNSL or IOL which has only achieved a PR after adequate
             initial therapy

          -  Must have CNS or intraocular involvement by NHL

          -  Subjects with secondary CNS NHL, relapsed PCNSL, or relapsed IOL will have received
             Salvage therapy for their CNS disease

          -  Subjects with synchronous CNS NHL will have received primary therapy including
             CNS-directed therapy

          -  Must demonstrate a partial or complete response of the CNS and systemic disease to
             pre-enrollment therapy, and must be in PR or CR at the time of enrollment

          -  Age &gt;/= 18 and &lt;/= 75 years

          -  Life expectancy &gt;/= 3 months

          -  ECOG performance status &lt;/= 2

          -  Must have adequate organ function as defined by the protocol

        Exclusion Criteria:

          -  Stable or progressive CNS or systemic disease (SD orPD) at the time of enrollment

          -  Systemic or intrathecal chemotherapy or radiotherapy within 2 weeks prior to starting
             therapy on study

          -  Actively receiving any other study agents aimed to treat their disease

          -  A prior HDT-ASCT or allogeneic stem cell transplant (myeloablative or
             nonmyeloablative)

          -  Burkitt's lymphoma or acute lymphoblastic lymphoma

          -  A history of severe allergic reactions attributed to compounds of similar chemical or
             biologic composition to cytarabine, thiotepa, busulfan, cyclophosphamide, or rituximab

          -  Serious uncontrolled concurrent illness

          -  Any evidence of prior exposure to Hepatitis B virus

          -  HIV-positive

          -  Pregnant or lactating

          -  A history of malignancy other than NHL or PCNSL unless disease-free for at least 5
             years and are deemed by the investigator to be at low risk for recurrence of that
             malignancy. Individuals with the following cancers are eligible if diagnosed and
             treated within the past 5 years: cervical cancer in situ, and basal cell or squamous
             cell carcinoma of the skin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yi-Bin A Chen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Chen YB, Batchelor T, Li S, Hochberg E, Brezina M, Jones S, Del Rio C, Curtis M, Ballen KK, Barnes J, Chi AS, Dietrich J, Driscoll J, Gertsner ER, Hochberg F, LaCasce AS, McAfee SL, Spitzer TR, Nayak L, Armand P. Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lymphoma. Cancer. 2015 Jan 15;121(2):226-33. doi: 10.1002/cncr.29023. Epub 2014 Sep 9.</citation>
    <PMID>25204639</PMID>
  </results_reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 30, 2010</study_first_submitted>
  <study_first_submitted_qc>August 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 16, 2010</study_first_posted>
  <results_first_submitted>November 27, 2017</results_first_submitted>
  <results_first_submitted_qc>November 27, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">December 29, 2017</results_first_posted>
  <last_update_submitted>November 27, 2017</last_update_submitted>
  <last_update_submitted_qc>November 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Yi-Bin A. Chen, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>CNS involvement</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thiotepa</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>High-dose Chemotherapy With Autologous Stem Cell Transplant</title>
          <description>Autologous stem cell transplant: Autologous stem cell transplant following high-dose chemotherapy
High-dose chemotherapy: High-dose chemotherapy with rituximab, thiotepa, busulfan, and cyclosphosphamide</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>High-dose Chemotherapy With Autologous Stem Cell Transplant</title>
          <description>Autologous stem cell transplant: Autologous stem cell transplant following high-dose chemotherapy
High-dose chemotherapy: High-dose chemotherapy with rituximab, thiotepa, busulfan, and cyclosphosphamide</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59" lower_limit="24" upper_limit="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Histology</title>
          <description>CLL: Chronic lymphocytic leukemia SLL: Small lymphocytic lymphoma</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Diffuse Large B-cell Lymphoma</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CLL/ SLL</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follicular Non-Hodgkin lymphoma</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior Treatment History</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>High-Dose Intravenous Methotrexate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High-Dose Cytarabine</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rituximab (Intravenous)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Whole brain radiation therapy (WBRT)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other Radiation Therapy</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Patients With CNS Involvement by B-cell NHL, Relapsed PCNSL, or Relapsed PIOL Who Are Alive and Progression-free at One Year</title>
        <description>The proportion of patients with central nervous system (CNS) involvement by B-cell Non-Hodgkin's Lymphoma (NHL), relapsed primary central nervous system lymphoma (PCNSL), or relapsed primary intraocular lymphoma (PIOL) who are alive and progression-free at one year</description>
        <time_frame>3 years</time_frame>
        <population>The participant that was lost to follow-up was not available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>High-dose Chemotherapy With Autologous Stem Cell Transplant</title>
            <description>Autologous stem cell transplant: Autologous stem cell transplant following high-dose chemotherapy
High-dose chemotherapy: High-dose chemotherapy with rituximab, thiotepa, busulfan, and cyclosphosphamide</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With CNS Involvement by B-cell NHL, Relapsed PCNSL, or Relapsed PIOL Who Are Alive and Progression-free at One Year</title>
          <description>The proportion of patients with central nervous system (CNS) involvement by B-cell Non-Hodgkin's Lymphoma (NHL), relapsed primary central nervous system lymphoma (PCNSL), or relapsed primary intraocular lymphoma (PIOL) who are alive and progression-free at one year</description>
          <population>The participant that was lost to follow-up was not available for analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>2-year Progression Free Survival (PFS)</title>
        <description>The percentage of participants alive and without disease progression at 2 years.</description>
        <time_frame>2 years</time_frame>
        <population>The participant that was lost to follow-up was not available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>High-dose Chemotherapy With Autologous Stem Cell Transplant</title>
            <description>Autologous stem cell transplant: Autologous stem cell transplant following high-dose chemotherapy
High-dose chemotherapy: High-dose chemotherapy with rituximab, thiotepa, busulfan, and cyclosphosphamide</description>
          </group>
        </group_list>
        <measure>
          <title>2-year Progression Free Survival (PFS)</title>
          <description>The percentage of participants alive and without disease progression at 2 years.</description>
          <population>The participant that was lost to follow-up was not available for analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81" lower_limit="59" upper_limit="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>2-year Overall Survival (OS)</title>
        <description>The percentage of participants alive after two years</description>
        <time_frame>2 years</time_frame>
        <population>The participant that was lost to follow-up was not available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>High-dose Chemotherapy With Autologous Stem Cell Transplant</title>
            <description>Autologous stem cell transplant: Autologous stem cell transplant following high-dose chemotherapy
High-dose chemotherapy: High-dose chemotherapy with rituximab, thiotepa, busulfan, and cyclosphosphamide</description>
          </group>
        </group_list>
        <measure>
          <title>2-year Overall Survival (OS)</title>
          <description>The percentage of participants alive after two years</description>
          <population>The participant that was lost to follow-up was not available for analysis.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93" lower_limit="76" upper_limit="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response Rate</title>
        <description>The number of participants that achieved complete remission following high dose chemotherapy and autologous stem cell transplantation (ASCT). Complete remission is defined as the disappearance of all evidence of disease.</description>
        <time_frame>3 years</time_frame>
        <population>The participant that was lost to follow-up was not available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>High-dose Chemotherapy With Autologous Stem Cell Transplant</title>
            <description>Autologous stem cell transplant: Autologous stem cell transplant following high-dose chemotherapy
High-dose chemotherapy: High-dose chemotherapy with rituximab, thiotepa, busulfan, and cyclosphosphamide</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate</title>
          <description>The number of participants that achieved complete remission following high dose chemotherapy and autologous stem cell transplantation (ASCT). Complete remission is defined as the disappearance of all evidence of disease.</description>
          <population>The participant that was lost to follow-up was not available for analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the start of treatment until disease progression, death, or until taken off study; median duration of 24 months.</time_frame>
      <desc>All grade 3 or greater adverse events were considered to be serious adverse events regardless of whether or not the adverse event was believed to be treatment related.</desc>
      <group_list>
        <group group_id="E1">
          <title>High-dose Chemotherapy With Autologous Stem Cell Transplant</title>
          <description>Autologous stem cell transplant: Autologous stem cell transplant following high-dose chemotherapy
High-dose chemotherapy: High-dose chemotherapy with rituximab, thiotepa, busulfan, and cyclosphosphamide</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Investigations - Other, specify</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Yi-Bin Chen</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>617-726-0187</phone>
      <email>YCHEN6@PARTNERS.ORG</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

